Products from BPS Bioscience require a minimum order value above 400€
Application: Study BCMA:CD3 complex formation and assess the binding of BsAbs to their dual-antigen targets simultaneously for drug discovery and high throughput screening (HTS).Note: Suitable for use with human serum, cell culture supernatants, and with purified proteins.
Background: Bispecific antibodies (BsAbs) are antibodies that have binding sites directed against different antigens or different epitopes of the same antigen. They are composed of heavy and light chains, and the appropriate chain matching is required for efficacy. To enhance the chance of chain matching and different applications, more than 30 different technologies have been developed, such as knob-into hole, ART-Ig, BiTE (bispecific cell engager) and others. They have gained attention for the treatment of cancer and other disorders due to their superior cytotoxicity effects and less development of resistance to their use. BsAbs can act as immune cell-cancer cell bridges, enhancing the killing potential of the immune cells. Current BsAbs have a CD3, CD16 or CD47 as one of the binding domains, and target CD19, PD-1, LAG-3, PSMA, mesothelin or other tumor antigens with the other. B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in nonmalignant tissue but almost universal expression on MM cells. So far FDA has approved two BCMA CAR-T therapies for the treatment of multiple myeloma.
Contraindications: This kit is compatible with up to 1% DMSO.
Description: The Bispecific BCMA:CD3 Bridging Chemiluminescence ELISA Kit is an ELISA designed to analyze the ability of Bispecific Antibodies (BsAbs) to bridge BCMA (B-Cell Maturation Antigen, also known as Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)) and CD3 (cluster of differentiation 3) for screening and profiling applications. This assay kit can determine if an anti-BCMA-anti-CD3 bispecific antibody binds to both targets simultaneously and bridges BCMA to CD3. The Bispecific BCMA:CD3 Bridging Chemiluminescence ELISA Assay Kit comes with enough recombinant human BCMA (amino acids 20-291), CD3- Containing Detection Reagent, and assay buffer for 100 enzyme reactions. This kit also includes Anti-BCMA-Anti-CD3 Bispecific Antibody as a positive control.
Storage Stability: This assay kit will perform optimally for up to 6 months from date of receipt when the materials are stored as directed.
Uniprot: Q02223
Warnings: Avoid freeze/thaw cycles
Biosafety Level: Not applicable (BSL-1)
References: Ma J., et al., 2021 Front Immunol. 12:626616. Ghosh A, et al., 2017 Leuk. Lymphoma. 2017; 6: 1-12Sanchez E., et al., 2018 Expert Rev Mol Diagn. 2018; 7: 1-11.Sohail A., et al., 2018 Immunotherapy. 10(4): 265-282.
Deutsch
English
